TargetBeta
ADORA3
adenosine A3 receptor · also AD026, A3AR · Adenosine receptors
2 programs in company-led studies act on ADORA3, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Caffeinerule | Boehringer Ingelheim | phase 4 | 302 running | ADORA1, ADORA2A, ADORA2B | ChEMBL |
| piclidenosonrule | Can-Fite BioPharma | phase 3 | 152 running | – | NCIt |
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
- Common Cold, 1 program
- COVID-19, 1 program
- Glaucoma, 1 program
- Keratoconjunctivitis Sicca, 1 program
- Neoplasms, 1 program
- Obesity, 1 program
- Pain, 1 program
- Pain, Postoperative, 1 program
- Psoriasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 7, 2027Caffeine · Boehringer Ingelheim · phase 4 · NCT07710768
- Aug 31, 2027piclidenoson · Can-Fite BioPharma · phase 3 · NCT07410455
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.